Eye Of The Pricing Storm: FDA's Woodcock Withstands Gale-Force Rhetoric
House committee members deliver a fierce, if not terribly substantive, critique of FDA review processes as part of a hearing on Turing and Valeant.
House committee members deliver a fierce, if not terribly substantive, critique of FDA review processes as part of a hearing on Turing and Valeant.